Stock Report

Download full stock data and analysis for free Last Updated: 12-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Mangalam Drugs Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: MANGALAM | BSE: 532637

₹36.46

up-down-arrow ₹1.58 (4.53%)

As on 11-Sep-2026IST

Market cap

info icon

₹58 Cr

Revenue (TTM)

info icon

₹232 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

0.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -15.11 -0.16 -22.17 -12.77 -9.52
EBIT 68.79 65.68 -549.97 -672.87 -190.73
Net Profit 42.18 44.98 -296.70 -210.25 -209.34
EPS 42.18 44.98 -296.71 -210.25 -209.34
Book Value -- -- 4.43 -0.42 7.42
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info 3.606.42-11.546.040.74
Net Margin info 0.021.10-16.432.11-2.46
Return on equity info -0.187.45-33.164.84-6.68
Return on Capital info 5.4312.53--8.551.23
Return on Assets info -0.083.54-11.221.92-2.72
Debt to Equity (x) info ----0.070.620.70

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
8.55
1.23
--
--
Peer Median
--
14.72
18.85
11.60
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-33.16

Lower than Peers by 43.88

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-33.16
4.84
-6.68
--
--
Peer Median
10.72
11.67
14.92
11.46
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-11.22

Lower than Peers by 17.80

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-11.22
1.92
-2.72
--
--
Peer Median
6.58
7.86
9.06
6.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-11.54

Lower than Peers by 24.13

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-11.54
6.04
0.74
--
--
Peer Median
12.59
15.03
14.71
12.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-16.43

Lower than Peers by 25.19

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-16.43
2.11
-2.46
--
--
Peer Median
8.76
9.33
8.49
10.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
7.33
1.51
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-22.17

Lower than Peers by 30.10

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-22.17
-13.66
--
--
--
Peer Median
7.93
10.27
11.85
9.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-583.49

Lower than Peers by 600.01

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-583.49
604.47
--
--
--
Peer Median
16.52
24.15
28.00
-3.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-296.70

Lower than Peers by 313.95

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-296.70
174.09
--
--
--
Peer Median
17.25
30.29
36.51
-0.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-296.71

Lower than Peers by 307.02

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-296.71
174.08
--
--
--
Peer Median
10.32
24.50
--
-6.82
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
4.50
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.07

Higher than Peers by 0.03

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
0.07
0.62
0.70
--
--
Peer Median
0.04
0.23
0.20
0.15
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
0.48
0.55
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.79

Lower than Peers by 0.95

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
0.79
1.04
1.07
--
--
Peer Median
1.74
1.79
1.96
2.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.27

Lower than Peers by 0.91

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
0.27
0.31
0.32
--
--
Peer Median
1.18
1.47
1.44
1.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-1.67

Lower than Peers by 9.43

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-1.67
1.32
0.20
--
--
Peer Median
7.76
9.42
8.58
15.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

17.34

Lower than Peers by 8.41

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
17.34
12.28
7.58
--
--
Peer Median
25.75
25.82
26.12
22.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.68

Higher than Peers by 0.02

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
0.68
0.91
1.10
--
--
Peer Median
0.66
0.75
0.77
0.65
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
38.43
27.67
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
150.51
122.43
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
171.53
98.76
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
17.41
51.34
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

-1.51

Lower than Peers by 47.88

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-1.51
17.48
--
--
--
Peer Median
46.37
39.70
33.48
37.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.60

Lower than Peers by 4.00

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
0.60
0.83
1.08
--
--
Peer Median
4.60
3.72
4.21
3.22
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
--
--
--
--
--
Peer Median
0.10
0.16
0.21
0.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-18.38

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
-18.38
5.59
13.75
--
--
Peer Median
--
30.23
29.90
28.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

58

Lower than Peers by 7,458

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Mangalam Drugs
58
117
147
--
--
Peer Median
7,516
4,851
2,099
15,272
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...